ENGOT-EN3-NSGO/PALEO: Letrozole-palbociclib combination for endometrial cancer
0 Views
administrator
07/17/23
Mansoor Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses the results of the Phase II trial ENGOT-EN3-NSGO/PALEO (NCT02730429). The trial evaluated letrozole-palbociclib combination versus letrozole-placebo combination in endometrial cancer. The outcome of the trial was positive, showing an increased progression-free survival from 3 months to 8 months. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
-
Category
Show more
Facebook Comments
No comments found